Ignite Creation Date:
2024-05-05 @ 6:33 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00501852
Status:
COMPLETED
Last Update Posted:
2012-05-08
First Post:
2007-07-13
Brief Title:
Efficacy and Safety of Four Doses of Glycopyrronium Bromide NVA237 in Patients With Stable Chronic Obstructive Pulmonary Disease COPD in Comparison to an Active Comparator Tiotropium
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled 4 Period Incomplete Block Cross-over Multi-center Multiple Dose 7 Days Dose-ranging Study to Assess the Efficacy and Safety of 4 Doses of NVA237 in Patients With Stable COPD Compared to Seven Days Treatment With Tiotropium 18μg Once Daily Open Label as an Active Control
Status:
COMPLETED
Status Verified Date:
2010-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the efficacy and safety of glycopyrronium bromide NVA237 in patients with stable COPD in comparison to an active comparator
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None